1. Home
  2. MRVI vs EOLS Comparison

MRVI vs EOLS Comparison

Compare MRVI & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRVI
  • EOLS
  • Stock Information
  • Founded
  • MRVI 2020
  • EOLS 2012
  • Country
  • MRVI United States
  • EOLS United States
  • Employees
  • MRVI N/A
  • EOLS N/A
  • Industry
  • MRVI Biotechnology: Pharmaceutical Preparations
  • EOLS Biotechnology: Pharmaceutical Preparations
  • Sector
  • MRVI Health Care
  • EOLS Health Care
  • Exchange
  • MRVI Nasdaq
  • EOLS Nasdaq
  • Market Cap
  • MRVI 809.2M
  • EOLS 702.2M
  • IPO Year
  • MRVI 2020
  • EOLS 2018
  • Fundamental
  • Price
  • MRVI $4.77
  • EOLS $10.51
  • Analyst Decision
  • MRVI Buy
  • EOLS Strong Buy
  • Analyst Count
  • MRVI 10
  • EOLS 6
  • Target Price
  • MRVI $10.28
  • EOLS $22.60
  • AVG Volume (30 Days)
  • MRVI 1.8M
  • EOLS 695.8K
  • Earning Date
  • MRVI 02-25-2025
  • EOLS 03-06-2025
  • Dividend Yield
  • MRVI N/A
  • EOLS N/A
  • EPS Growth
  • MRVI N/A
  • EOLS N/A
  • EPS
  • MRVI N/A
  • EOLS N/A
  • Revenue
  • MRVI $276,920,000.00
  • EOLS $248,326,000.00
  • Revenue This Year
  • MRVI N/A
  • EOLS $33.43
  • Revenue Next Year
  • MRVI $2.25
  • EOLS $32.44
  • P/E Ratio
  • MRVI N/A
  • EOLS N/A
  • Revenue Growth
  • MRVI N/A
  • EOLS 34.42
  • 52 Week Low
  • MRVI $4.28
  • EOLS $9.25
  • 52 Week High
  • MRVI $11.56
  • EOLS $17.82
  • Technical
  • Relative Strength Index (RSI)
  • MRVI 39.85
  • EOLS 42.77
  • Support Level
  • MRVI $4.38
  • EOLS $9.25
  • Resistance Level
  • MRVI $6.21
  • EOLS $11.66
  • Average True Range (ATR)
  • MRVI 0.39
  • EOLS 0.55
  • MACD
  • MRVI -0.09
  • EOLS 0.06
  • Stochastic Oscillator
  • MRVI 21.31
  • EOLS 52.28

About MRVI Maravai LifeSciences Holdings Inc.

Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, and novel vaccines and supports research on human diseases. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Share on Social Networks: